Amount of H Antigen Expressed on Circulating von Willebrand Factor Is Modified by ABO Blood Group Genotype and Is a Major Determinant of Plasma von …
J O'Donnell, FE Boulton, RA Manning… - … , and vascular biology, 2002 - Am Heart Assoc
To investigate whether the effect of ABO blood group on plasma von Willebrand factor (vWF)
levels is mediated by the ABH antigenic determinants carried on N-linked glycans of vWF …
levels is mediated by the ABH antigenic determinants carried on N-linked glycans of vWF …
Problems of anticoagulation with warfarin in hyperthyroidism
HA Kellett, JSA Sawers, FE Boulton… - … Journal of Medicine, 1986 - academic.oup.com
From clinical observation it would appear that hyperthyroid patients are particularly sensitive
to the anticoagulant effects of warfarin. A study was made of clotting factors prothrombin (II) …
to the anticoagulant effects of warfarin. A study was made of clotting factors prothrombin (II) …
Genotype at the Secretor blood group locus is a determinant of plasma von Willebrand factor level
J O'Donnell, FE Boulton, RA Manning… - British journal of …, 2002 - Wiley Online Library
Previous reports on the effect of Secretor and Lewis blood groups on plasma factor VIII–von
Willebrand factor (FVIII–VWF) levels have produced conflicting findings. To determine …
Willebrand factor (FVIII–VWF) levels have produced conflicting findings. To determine …
Blood transfusion; additional historical aspects. Part 1. The birth of transfusion immunology
FE Boulton - Transfusion Medicine, 2013 - Wiley Online Library
The decades around the turn of the 19th into the 20th centuries covered a seminal period in
the history of transfusion medicine as there was an increasing appreciation of a potential …
the history of transfusion medicine as there was an increasing appreciation of a potential …
[PDF][PDF] Guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion
…, FE Boulton… - Transfusion …, 2007 - gjjyyxw.com
Guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit
autologous blood donation and transfusion Page 1 Transfusion Medicine, 2007, 17, 354–365 …
autologous blood donation and transfusion Page 1 Transfusion Medicine, 2007, 17, 354–365 …
[PDF][PDF] Guidelines for implementation of maximum surgical blood order schedule
JAF Napier, FE Boulton, R Cann… - Clinic Lab …, 1990 - infectedbloodinquiry.org.uk
Blood transfusion Iaboratories have experienced gradually increasing work loads without
any corresponding increase in trained staff; this has become more acute during the past five …
any corresponding increase in trained staff; this has become more acute during the past five …
Improved strategy for screening prospective blood donors for anaemia
FE Boulton, MJ Nightingale… - Transfusion Medicine, 1994 - Wiley Online Library
Women (568) and men (531) attending blood donation sessions in Wessex in September,
1992, were assessed for anaemia by the standard CuSO4 method on finger‐prick (FP) …
1992, were assessed for anaemia by the standard CuSO4 method on finger‐prick (FP) …
A Fatal Transfusion Reaction Associated with Blood Contaminated with Pseudomonas fluorescens
J Scott, FE Boulton, JRW Govan, RS Miles… - Vox …, 1988 - Wiley Online Library
A fatal transfusion reaction due to contamination of platelet‐depleted whole blood with
Pseudomonas fluorescens is reported. Routine sterility testing on blood products and …
Pseudomonas fluorescens is reported. Routine sterility testing on blood products and …
A comparative study using immunological and biological assays of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men
CV Prowse, A Farrugia, FE Boulton… - Thrombosis and …, 1984 - thieme-connect.com
In a group of six normal male volunteers, infusion of DDAVP, venous occlusion and exercise
were shown to increase plasma levels of factor VIII and plasminogen activator, activity and …
were shown to increase plasma levels of factor VIII and plasminogen activator, activity and …
Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.
M Been, DP De Bono, AL Muir, FE Boulton, WS Hillis… - Heart, 1985 - heart.bmj.com
BRL 26921 is a protected plasminogen-streptokinase complex with selective affinity for
thrombus. When given intravenously within three hours of the onset of a first acute …
thrombus. When given intravenously within three hours of the onset of a first acute …